Newsroom | 4628 results
Sorted by: Latest
-
Independent Recognition Reinforces Auragens' Position as a Global Leader in Regenerative Medicine
LAS VEGAS & PANAMA CITY, Panama--(BUSINESS WIRE)--Auragens today announced it has been named Stem Cell Treatment Center of the Year 2026 by Life Sciences Review, becoming the first organization to receive the publication's highest distinction for two consecutive years. While the award recognizes excellence in patient care, it also reflects a broader transformation taking place within regenerative medicine—one in which scientific rigor, manufacturing quality, regulatory oversight, and integrated...
-
Takara Bio USA, Inc. Announces the Retirement of Carol Lou, Appoints Andrew Farmer as President and CEO
SAN JOSE, Calif.--(BUSINESS WIRE)--President & CEO of Takara Bio USA Carol Lou announces she is retiring after 20 years of service, with Andrew Farmer as her successor....
-
Neo7Bioscience Announces Precision Signal Interception as a Transformative Approach to Pancreatic Cancer Treatment, Surpassing Limitations of Conventional RAS Pathway Suppression
DALLAS & FORT WORTH, Texas--(BUSINESS WIRE)--Neo7Bioscience Announces Precision Signal Interception for Pancreatic Cancer Treatment Beyond Conventional RAS Pathway Suppression...
-
Riassunto: STEMCELL Technologies e CCRM collaborano per ampliare l'accesso a linee iPSC conformi alle norme GMP e RUO per lo sviluppo della terapia cellulare
VANCOUVER, British Columbia e TORONTO--(BUSINESS WIRE)--STEMCELL Technologies e il Centre for Commercialization of Regenerative Medicine (CCRM) oggi ha annunciato una collaborazione per ampliare l'accesso a materiali di partenza di alta qualità derivati da cellule staminali pluripotenti indotte umane (iPSC), offrendo agli sviluppatori di terapie cellulari di tutto il mondo un percorso più rapido e meno rischioso dalla ricerca alla clinica. Il testo originale del presente annuncio, redatto nella...
-
Samenvatting: STEMCELL Technologies en CCRM gaan samenwerken om de toegang tot op elkaar afgestemde GMP- en RUO-iPSC-lijnen voor de ontwikkeling van celtherapieën te vergroten
VANCOUVER, Brits-Columbia & TORONTO--(BUSINESS WIRE)--STEMCELL Technologies en het Centre for Commercialization of Regenerative Medicine (CCRM) hebben vandaag een samenwerking aangekondigd om de toegang tot hoogwaardig uitgangsmateriaal in de vorm van menselijke geïnduceerde pluripotente stamcellen (iPSC’s) te vergroten. Dit geeft ontwikkelaars van celtherapieën wereldwijd een snellere en minder risicovolle oplossing van onderzoek naar de klinische praktijk. Deze bekendmaking is officieel gelde...
-
STEMCELL Technologies et le CCRM s’associent pour élargir l’accès à des lignées de CSPi conformes aux normes BPF et à des lignées de CSPi RUO appariées, en vue du développement de thérapies cellulaires
VANCOUVER, Colombie-Britannique et TORONTO--(BUSINESS WIRE)--STEMCELL Technologies et le Centre for Commercialization of Regenerative Medicine (CCRM) ont annoncé aujourd’hui un partenariat visant à élargir l’accès à des matériaux de départ de haute qualité issus de cellules souches pluripotentes induites (CSPi) humaines, offrant ainsi aux développeurs de thérapies cellulaires du monde entier une voie plus rapide et moins risquée pour passer de la recherche à la pratique clinique. Dans le cadre...
-
Resumen: STEMCELL Technologies y CCRM se asocian para ampliar el acceso a líneas de células iPSC compatibles, tanto de GMP como de RUO, para el desarrollo de terapias celulares
VANCOUVER, Columbia Británica y TORONTO--(BUSINESS WIRE)--STEMCELL Technologies y el Centre for Commercialization of Regenerative Medicine (CCRM) han anunciado hoy una alianza para ampliar el acceso a materiales de partida de alta calidad a base de células madre pluripotentes inducidas (iPSC) humanas, lo que ofrecerá a los desarrolladores de terapias celulares de todo el mundo una vía más rápida y con menos riesgos desde la investigación hasta la aplicación clínica. El comunicado en el idioma o...
-
STEMCELL Technologies und CCRM schließen Partnerschaft, um den Zugang zu aufeinander abgestimmten GMP- und RUO-iPSC-Linien für die Entwicklung von Zelltherapien zu erweitern
VANCOUVER, British Columbia & TORONTO--(BUSINESS WIRE)--STEMCELL Technologies und das Centre for Commercialization of Regenerative Medicine (CCRM) gaben heute eine Partnerschaft bekannt, um den Zugang zu hochwertigen Ausgangsmaterialien aus humanen induzierten pluripotenten Stammzellen (iPS-Zellen) zu erweitern und Entwicklern von Zelltherapien weltweit einen schnelleren und risikoärmeren Weg von der Forschung in die klinische Anwendung zu ermöglichen. Im Rahmen der Vereinbarung wird STEMCELL i...
-
MEDIPOST Inc. Treats First U.S. Participant in Phase III Trial of Umbilical Cord Stem Cell Therapy for Symptomatic Cartilage Defects Due to Knee Osteoarthritis
CAMBRIDGE, Mass.--(BUSINESS WIRE)--MEDIPOST Inc., a biotechnology company developing allogeneic, umbilical cord blood-derived stem cell therapies for inflammation-driven degenerative diseases, announced today the treatment of the first U.S. participant in its Phase III clinical trial evaluating its investigational mesenchymal stem cell (MSC) therapy to treat symptomatic cartilage defects in adults with knee osteoarthritis. The FDA has agreed that this single pivotal study, supported by confirma...
-
STEMCELL Technologies and CCRM Partner to Expand Access to Matched GMP and RUO iPSC Lines for Cell Therapy Development
VANCOUVER, British Columbia & TORONTO--(BUSINESS WIRE)--STEMCELL Technologies and the Centre for Commercialization of Regenerative Medicine (CCRM) today announced a partnership to expand access to high-quality human induced pluripotent stem cell (iPSC) starting materials, giving cell therapy developers worldwide a faster, lower-risk path from research to the clinic. Under the agreement, STEMCELL will manufacture and distribute research-use-only (RUO) iPSC lines derived directly from LineaBio's...
